Hansoh Pharmaceutical (03692): HS-20197 for Injection Receives Drug Clinical Trial Approval Notice Issued by the National Medical Products Administration

Zhitong Finance APP news, Hansoh Pharmaceutical (03692) announced that on September 11, 2026, the Group's independently developed Class 1 new drug HS-20197 for injection received a drug clinical trial approval notice issued by China's National Medical Products Administration (NMPA), and is intended for clinical trials for "advanced solid tumors."